https://insights.citeline.comTue, 12 Nov 2024 09:03:22 +0000en1hourly1https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/looking-for-stars-us-fda-expands-split-real-time-review-amid-low-supplement-interest-V5SRGEVE4RCXLO5TERLIK4RFBI/https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/looking-for-stars-us-fda-expands-split-real-time-review-amid-low-supplement-interest-V5SRGEVE4RCXLO5TERLIK4RFBI/Mon, 11 Nov 2024 21:56:35 +0000https://insights.citeline.com/scrip/japan-h1-roundup-forex-impact-strong-global-mainstays-positive-factors-PJXPS55ZSBFPZPUVU33BEHK4DE/https://insights.citeline.com/scrip/japan-h1-roundup-forex-impact-strong-global-mainstays-positive-factors-PJXPS55ZSBFPZPUVU33BEHK4DE/Mon, 11 Nov 2024 09:09:00 +0000https://insights.citeline.com/hbw-insight/beauty/innovationandip/new-products/factorfives-stem-cell-based-skin-care-benefits-exceed-promotional-claims-ceo-SSHJ2LAGYBA45DPWIVG564UJMA/https://insights.citeline.com/hbw-insight/beauty/innovationandip/new-products/factorfives-stem-cell-based-skin-care-benefits-exceed-promotional-claims-ceo-SSHJ2LAGYBA45DPWIVG564UJMA/Mon, 11 Nov 2024 23:23:43 +0000Shutterstockhttps://insights.citeline.com/pink-sheet/compliance/marketing-and-advertising/chinese-regulator-raises-red-flag-on-clinical-trial-bribery-6SHO5XBFURF4PIGJJ4ONKAP7XU/https://insights.citeline.com/pink-sheet/compliance/marketing-and-advertising/chinese-regulator-raises-red-flag-on-clinical-trial-bribery-6SHO5XBFURF4PIGJJ4ONKAP7XU/Tue, 12 Nov 2024 00:03:29 +0000https://insights.citeline.com/pink-sheet/japan-recommends-approval-of-brukinza-balversa-7KRG7Y3IEVFFLD27P6TZVEUD4U/https://insights.citeline.com/pink-sheet/japan-recommends-approval-of-brukinza-balversa-7KRG7Y3IEVFFLD27P6TZVEUD4U/Mon, 11 Nov 2024 05:12:11 +0000https://insights.citeline.com/companies/peak-bio-co-ltdhttps://insights.citeline.com/companies/peak-bio-co-ltdTue, 12 Nov 2024 00:03:40 +0000https://insights.citeline.com/companies/physician-recommended-nutriceuticalshttps://insights.citeline.com/companies/physician-recommended-nutriceuticalsTue, 12 Nov 2024 00:03:37 +0000https://insights.citeline.com/companies/helixnanohttps://insights.citeline.com/companies/helixnanoTue, 12 Nov 2024 00:03:34 +0000https://insights.citeline.com/companies/traws-pharma-inchttps://insights.citeline.com/companies/traws-pharma-incTue, 12 Nov 2024 00:03:31 +0000https://insights.citeline.com/companies/adare-pharma-solutionshttps://insights.citeline.com/companies/adare-pharma-solutionsTue, 12 Nov 2024 00:03:28 +0000https://insights.citeline.com/companies/maxvax-biotechnology-ltdhttps://insights.citeline.com/companies/maxvax-biotechnology-ltdTue, 12 Nov 2024 00:03:22 +0000https://insights.citeline.com/companies/tuhura-biosciences-inchttps://insights.citeline.com/companies/tuhura-biosciences-incTue, 12 Nov 2024 00:03:19 +0000https://insights.citeline.com/companies/wisconsin-alumni-research-foundationhttps://insights.citeline.com/companies/wisconsin-alumni-research-foundationTue, 12 Nov 2024 00:03:16 +0000https://insights.citeline.com/companies/edgewood-oncologyhttps://insights.citeline.com/companies/edgewood-oncologyTue, 12 Nov 2024 00:03:13 +0000https://insights.citeline.com/companies/stryker-corporationhttps://insights.citeline.com/companies/stryker-corporationTue, 12 Nov 2024 00:03:10 +0000https://insights.citeline.com/companies/aditxt-inchttps://insights.citeline.com/companies/aditxt-incTue, 12 Nov 2024 00:03:04 +0000https://insights.citeline.com/companies/century-therapeutics-inchttps://insights.citeline.com/companies/century-therapeutics-incTue, 12 Nov 2024 00:02:52 +0000https://insights.citeline.com/companies/ucb-sahttps://insights.citeline.com/companies/ucb-saTue, 12 Nov 2024 00:02:46 +0000https://insights.citeline.com/companies/epibone-inchttps://insights.citeline.com/companies/epibone-incTue, 12 Nov 2024 00:02:40 +0000https://insights.citeline.com/companies/lensar-inchttps://insights.citeline.com/companies/lensar-incTue, 12 Nov 2024 00:02:34 +0000https://insights.citeline.com/companies/orchard-therapeutics-limitedhttps://insights.citeline.com/companies/orchard-therapeutics-limitedTue, 12 Nov 2024 00:02:28 +0000https://insights.citeline.com/companies/neubase-therapeutics-inchttps://insights.citeline.com/companies/neubase-therapeutics-incTue, 12 Nov 2024 00:02:22 +0000https://insights.citeline.com/companies/biosergen-ashttps://insights.citeline.com/companies/biosergen-asTue, 12 Nov 2024 00:02:16 +0000https://insights.citeline.com/companies/evofem-biosciences-inchttps://insights.citeline.com/companies/evofem-biosciences-incTue, 12 Nov 2024 00:02:10 +0000https://insights.citeline.com/companies/vicarious-surgical-inchttps://insights.citeline.com/companies/vicarious-surgical-incTue, 12 Nov 2024 00:02:04 +0000https://insights.citeline.com/companies/qyuns-therapeutics-co-ltdhttps://insights.citeline.com/companies/qyuns-therapeutics-co-ltdTue, 12 Nov 2024 00:01:57 +0000https://insights.citeline.com/companies/sqz-biotechnologies-companyhttps://insights.citeline.com/companies/sqz-biotechnologies-companyTue, 12 Nov 2024 00:01:55 +0000https://insights.citeline.com/companies/affluent-medical-sahttps://insights.citeline.com/companies/affluent-medical-saTue, 12 Nov 2024 00:01:46 +0000https://insights.citeline.com/companies/gsk-plchttps://insights.citeline.com/companies/gsk-plcTue, 12 Nov 2024 00:01:39 +0000https://insights.citeline.com/companies/valerio-therapeuticshttps://insights.citeline.com/companies/valerio-therapeuticsTue, 12 Nov 2024 00:01:34 +0000https://insights.citeline.com/companies/medarexhttps://insights.citeline.com/companies/medarexTue, 12 Nov 2024 00:01:28 +0000https://insights.citeline.com/companies/harrow-inchttps://insights.citeline.com/companies/harrow-incTue, 12 Nov 2024 00:01:26 +0000https://insights.citeline.com/companies/scisparc-ltdhttps://insights.citeline.com/companies/scisparc-ltdTue, 12 Nov 2024 00:01:23 +0000https://insights.citeline.com/companies/seagen-inchttps://insights.citeline.com/companies/seagen-incTue, 12 Nov 2024 00:01:21 +0000https://insights.citeline.com/medtech-insight/business/r-and-d/octave-biosciences-multi-biomarker-test-provides-key-insights-to-predict-multiple-sclerosis-disease-state-MLNWIXUBWZGERLRXESTLSZQ7GY/https://insights.citeline.com/medtech-insight/business/r-and-d/octave-biosciences-multi-biomarker-test-provides-key-insights-to-predict-multiple-sclerosis-disease-state-MLNWIXUBWZGERLRXESTLSZQ7GY/Mon, 11 Nov 2024 23:40:08 +0000Shutterstockhttps://insights.citeline.com/scrip/business/earnings/eisai-cuts-us-leqembi-sales-forecast-but-japan-china-exceed-expectations-LVF5AVGQSBH4ZA6O2UVGCLPHMI/https://insights.citeline.com/scrip/business/earnings/eisai-cuts-us-leqembi-sales-forecast-but-japan-china-exceed-expectations-LVF5AVGQSBH4ZA6O2UVGCLPHMI/Mon, 11 Nov 2024 23:32:34 +0000https://insights.citeline.com/scrip/r-and-d/clinical-trials/value-of-abbvies-cerevel-buy-uncertain-after-schizophrenia-failure-H4DMM5A3INHV3IXLCN64CAMR3E/https://insights.citeline.com/scrip/r-and-d/clinical-trials/value-of-abbvies-cerevel-buy-uncertain-after-schizophrenia-failure-H4DMM5A3INHV3IXLCN64CAMR3E/Mon, 11 Nov 2024 22:50:29 +0000https://insights.citeline.com/scrip/r-and-d/pipeline-watch/pipeline-watch-sanofiregenerons-dupixent-gets-eu-eosinophilic-esophagitis-approved-for-young-children-VHKLSHWLKVGSXND26LSLTFDI2U/https://insights.citeline.com/scrip/r-and-d/pipeline-watch/pipeline-watch-sanofiregenerons-dupixent-gets-eu-eosinophilic-esophagitis-approved-for-young-children-VHKLSHWLKVGSXND26LSLTFDI2U/Mon, 11 Nov 2024 15:05:01 +0000https://insights.citeline.com/scrip/business/earnings/almirall-insists-costly-ebglyss-launch-is-progressing-well-JGVUHZGENBDBVKZEMMYWGYTMNI/https://insights.citeline.com/scrip/business/earnings/almirall-insists-costly-ebglyss-launch-is-progressing-well-JGVUHZGENBDBVKZEMMYWGYTMNI/Mon, 11 Nov 2024 15:27:29 +0000https://insights.citeline.com/scrip/business/strategy/muscling-into-the-obesity-market-HHUWSZFWXJA33BUB2VAGEATRYQ/https://insights.citeline.com/scrip/business/strategy/muscling-into-the-obesity-market-HHUWSZFWXJA33BUB2VAGEATRYQ/Mon, 11 Nov 2024 15:59:49 +0000https://insights.citeline.com/scrip/advanced-therapies/cell-therapies/autoluss-newly-approved-car-t-aucatzyl-could-take-the-lead-on-safety-ZI6R3Y6CGNCFJGDIOED2OFI5JQ/https://insights.citeline.com/scrip/advanced-therapies/cell-therapies/autoluss-newly-approved-car-t-aucatzyl-could-take-the-lead-on-safety-ZI6R3Y6CGNCFJGDIOED2OFI5JQ/Mon, 11 Nov 2024 16:56:33 +0000https://insights.citeline.com/scrip/therapeutic-category/immunological/rapt-scraps-zelnecirnon-but-not-giving-up-on-ccr4-RZ22FTLM4RGTVBY6BVWTWIMX5U/https://insights.citeline.com/scrip/therapeutic-category/immunological/rapt-scraps-zelnecirnon-but-not-giving-up-on-ccr4-RZ22FTLM4RGTVBY6BVWTWIMX5U/Mon, 11 Nov 2024 20:38:37 +0000https://insights.citeline.com/pink-sheet/rare-diseases/woodcock-on-new-rare-rx-approval-pathway-us-fdas-current-flexibilities-come-too-late-3CNIRTHQBFDPLL7VK56TCBUJ5E/https://insights.citeline.com/pink-sheet/rare-diseases/woodcock-on-new-rare-rx-approval-pathway-us-fdas-current-flexibilities-come-too-late-3CNIRTHQBFDPLL7VK56TCBUJ5E/Mon, 11 Nov 2024 22:04:05 +0000https://insights.citeline.com/hbw-insight/health/rx-to-otc-switch/denmark-switches-nalxone-to-otc-status-42BGMVPW75CNPGYLEBSJF6HYU4/https://insights.citeline.com/hbw-insight/health/rx-to-otc-switch/denmark-switches-nalxone-to-otc-status-42BGMVPW75CNPGYLEBSJF6HYU4/Mon, 11 Nov 2024 16:54:32 +0000https://insights.citeline.com/hbw-insight/wellness/policy-and-regulation/supplement-firms-could-lighten-fda-inspection-load-need-lighter-drug-preclusion-touch-crn-5A4AEFOGG5EEHKFS3525NZZZXQ/https://insights.citeline.com/hbw-insight/wellness/policy-and-regulation/supplement-firms-could-lighten-fda-inspection-load-need-lighter-drug-preclusion-touch-crn-5A4AEFOGG5EEHKFS3525NZZZXQ/Mon, 11 Nov 2024 22:09:00 +0000https://insights.citeline.com/pink-sheet/uk-toolkit-to-accelerate-research-set-up-across-england-ni-scotland-wales-FPOUNPTWKVDHNLFROTMOATKYHU/https://insights.citeline.com/pink-sheet/uk-toolkit-to-accelerate-research-set-up-across-england-ni-scotland-wales-FPOUNPTWKVDHNLFROTMOATKYHU/Mon, 11 Nov 2024 13:04:14 +0000https://insights.citeline.com/pink-sheet/legislation/elections/anticipation-and-trepidation-about-trumps-election-rise-YTCHNKQW4VA3PPY3GBF3BQLAOQ/https://insights.citeline.com/pink-sheet/legislation/elections/anticipation-and-trepidation-about-trumps-election-rise-YTCHNKQW4VA3PPY3GBF3BQLAOQ/Mon, 11 Nov 2024 21:58:36 +0000https://insights.citeline.com/pink-sheet/agency-leadership/uk-mhra-at-least-half-of-novel-drug-filings-to-take-national-assessment-route-P537X5RTI5CUHBUINYQHWC6SPI/https://insights.citeline.com/pink-sheet/agency-leadership/uk-mhra-at-least-half-of-novel-drug-filings-to-take-national-assessment-route-P537X5RTI5CUHBUINYQHWC6SPI/Mon, 11 Nov 2024 14:18:25 +0000https://insights.citeline.com/in-vivo/leadership/execs-on-the-move-october-2024-EP2OKIFHCFF5TGAFRVGWWRBRYE/https://insights.citeline.com/in-vivo/leadership/execs-on-the-move-october-2024-EP2OKIFHCFF5TGAFRVGWWRBRYE/Mon, 11 Nov 2024 13:12:56 +0000https://insights.citeline.com/in-vivo/outlook/uncertainty-remains-over-the-future-of-regulatory-data-protection-in-the-eu-RE4UXBQMG5HGVNBQY6MPBWRUQE/https://insights.citeline.com/in-vivo/outlook/uncertainty-remains-over-the-future-of-regulatory-data-protection-in-the-eu-RE4UXBQMG5HGVNBQY6MPBWRUQE/Mon, 11 Nov 2024 13:10:38 +0000JLBvdWOLF / Alamy Stock Photohttps://insights.citeline.com/in-vivo/manufacturing/atmp-manufacturing-complex-challenges-require-complex-solutions-NECIJ5PLEBERLBA3BXUER2JIT4/https://insights.citeline.com/in-vivo/manufacturing/atmp-manufacturing-complex-challenges-require-complex-solutions-NECIJ5PLEBERLBA3BXUER2JIT4/Mon, 11 Nov 2024 13:09:21 +0000https://insights.citeline.com/in-vivo/outlook/neoadjuvant-cancer-immunotherapy-set-for-takeoff-fueled-by-strong-data-CXI6UE7AJBAB5PD4Q4ZZ6RCT3U/https://insights.citeline.com/in-vivo/outlook/neoadjuvant-cancer-immunotherapy-set-for-takeoff-fueled-by-strong-data-CXI6UE7AJBAB5PD4Q4ZZ6RCT3U/Mon, 11 Nov 2024 13:07:25 +0000https://insights.citeline.com/generics-bulletin/business/earnings/hikma-stays-on-track-by-bolstering-injectables-and-generics-YJ4TXEAWQVH7ZIDPKPYNPHWARA/https://insights.citeline.com/generics-bulletin/business/earnings/hikma-stays-on-track-by-bolstering-injectables-and-generics-YJ4TXEAWQVH7ZIDPKPYNPHWARA/Mon, 11 Nov 2024 12:23:22 +0000https://insights.citeline.com/generics-bulletin/products/value-added-medicines/teva-welcomes-potential-for-olanzapine-running-start-amid-positive-clinical-data-SG5B2Z5YRRBWPD4ENUJVWPK6G4/https://insights.citeline.com/generics-bulletin/products/value-added-medicines/teva-welcomes-potential-for-olanzapine-running-start-amid-positive-clinical-data-SG5B2Z5YRRBWPD4ENUJVWPK6G4/Mon, 11 Nov 2024 12:08:21 +0000https://insights.citeline.com/generics-bulletin/products/biosimilars/igba-kicks-off-global-biosimilars-week-2024-A4NJ4ZSDTBBJNE6Y4MCRVML6DI/https://insights.citeline.com/generics-bulletin/products/biosimilars/igba-kicks-off-global-biosimilars-week-2024-A4NJ4ZSDTBBJNE6Y4MCRVML6DI/Mon, 11 Nov 2024 11:59:01 +0000https://insights.citeline.com/scrip/profile-msd-janssen-to-bsv-mankind-deal-navanguls-journey-is-a-rich-mosaic-OZCIEED74ZAXHKYY4JFLBUWWSY/https://insights.citeline.com/scrip/profile-msd-janssen-to-bsv-mankind-deal-navanguls-journey-is-a-rich-mosaic-OZCIEED74ZAXHKYY4JFLBUWWSY/Mon, 11 Nov 2024 07:41:40 +0000https://insights.citeline.com/scrip/quick-listen-scrips-five-must-know-things-D4FI3E5BCNF2HNIP6TPK5KQ2A4/https://insights.citeline.com/scrip/quick-listen-scrips-five-must-know-things-D4FI3E5BCNF2HNIP6TPK5KQ2A4/Mon, 11 Nov 2024 02:40:27 +0000https://insights.citeline.com/hbw-insight/wellness/business/marketing-and-advertising/us-consumer-health-sports-marketing-opillwnba-recover-180nba-bucked-upmcgregor-IRHYKPVE5RFZDPAWBN5DDBVIHI/https://insights.citeline.com/hbw-insight/wellness/business/marketing-and-advertising/us-consumer-health-sports-marketing-opillwnba-recover-180nba-bucked-upmcgregor-IRHYKPVE5RFZDPAWBN5DDBVIHI/Mon, 11 Nov 2024 00:54:44 +0000https://insights.citeline.com/hbw-insight/digital-technologies/more-than-half-of-medicine-users-ignore-patient-information-leaflets-pagb-review-finds-FERMOTRDT5F7LHS6OQ6QZRVGLY/https://insights.citeline.com/hbw-insight/digital-technologies/more-than-half-of-medicine-users-ignore-patient-information-leaflets-pagb-review-finds-FERMOTRDT5F7LHS6OQ6QZRVGLY/Mon, 11 Nov 2024 00:12:45 +0000